Document Detail

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
MedLine Citation:
PMID:  21222185     Owner:  NLM     Status:  MEDLINE    
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive and life-threatening disease characterized by complement-mediated chronic hemolysis, resulting in serious life-threatening complications and early mortality. Eculizumab, a humanized anti-C5 monoclonal antibody that inhibits terminal complement activation, has been shown to reduce hemolysis in PNH patients. The pivotal open-label, 12-week phase II registration study (AEGIS) was designed to evaluate the efficacy and safety of eculizumab in Japanese patients with PNH. This trial achieved its primary endpoint of reducing intravascular hemolysis with high statistical significance. Twenty-seven of the 29 patients responded to eculizumab treatment, resulting in an 87% reduction in hemolysis (P < 0.0001) and subsequent improvement in anemia (P = 0.0003) despite reduction in transfusion requirements (P = 0.006). Fatigue and dyspnea significantly improved within 1-2 weeks of eculizumab treatment and the improvement was independent of changes in hemoglobin. Chronic kidney disease (CKD) was common (66%) and eculizumab treatment improved CKD in 41% of patients at 12 weeks (P < 0.001). Elevated thrombotic risk was evident in Japanese PNH patients and eculizumab treatment normalized D: -dimer levels in 45% of patients with elevated D: -dimers at baseline (P < 0.001). The AEGIS results demonstrate that eculizumab is effective, safe and well tolerated in Japanese patients with PNH.
Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Marye Ellen Valentine; Gus Khursigara; Keiya Ozawa; Mitsuhiro Omine
Related Documents :
8128945 - Increased ascitic fluid prorenin in the ovarian hyperstimulation syndrome.
14662785 - Seminal antioxidant capacity in pre- and postoperative varicocele.
10884745 - The incidence and significance of testicular microlithiasis in a subfertile population.
7965425 - True hermaphroditism: genetic variants and clinical management.
12516685 - Endothelial dysfunction associated with chronic intravascular coagulation in secondary ...
22551665 - Metabolic brain pet pattern underlying hyperkinetic seizures.
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study     Date:  2011-01-12
Journal Detail:
Title:  International journal of hematology     Volume:  93     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-14     Completed Date:  2011-05-03     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  36-46     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Antibodies, Monoclonal, Humanized
Asian Continental Ancestry Group
Complement Activation / drug effects
Complement C5 / antagonists & inhibitors*,  metabolism
Fibrin Fibrinogen Degradation Products / analysis
Hemoglobinuria, Paroxysmal / blood,  drug therapy*
Hemolysis / drug effects
Middle Aged
Risk Factors
Thrombosis / blood,  chemically induced
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Complement C5; 0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D; A3ULP0F556/eculizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Erythropoiesis, anemia and the bone marrow microenvironment.
Next Document:  Heat stress enhances mTOR signaling after resistance exercise in human skeletal muscle.